Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Biphenyl. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.56 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.56 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.56 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP7 | P09237 | 1/20 | 0.48 |
| ▸ | MMP14 | P50281 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycine SCHEMBL252376 | 0.88 | GLRA1 (0.62) | LMNAPTGS1ABCC4GAATSHR | |
| Biphenyl SCHEMBL9843146 | 0.86 | KDM4E (0.52) | LMNAPTGS1ABCC4GAATSHR | |
| Biphenyl SCHEMBL27334830 | 0.85 | ALDH1A1 (0.60) | LMNAPTGS1ABCC4GAATSHR | |
| Biphenyl SCHEMBL29081077 | 0.84 | FFAR1 (0.59) | LMNAPTGS1ABCC4GAATSHR | |
| Glycine SCHEMBL17260991 | 0.84 | AOC3 (0.50) | LMNAPTGS1ABCC4GAATSHR | |
| Naphthalene SCHEMBL3892974 | 0.83 | GLRA1 (0.56) | TSHRGLRA1SLC6A9OR51E2FFAR1 | |
| Glycine SCHEMBL8217220 | 0.83 | TP53 (0.48) | LMNAPTGS1ABCC4GAATSHR | |
| Glycine SCHEMBL27936916 | 0.82 | FFAR1 (0.47) | LMNAPTGS1ABCC4GAATSHR | |
| Benzene SCHEMBL7131871 | 0.82 | GLRA1 (0.83) | LMNATSHRGLRA1SLC6A9OR51E2 | |
| Aniline SCHEMBL11191296 | 0.81 | TSHR (0.58) | TSHRGLRA1SLC6A9OR51E2FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11897970-B2 | Antibacterial products | THE UNIVERSITY OF LIVERPOOL (GB) | 2024-02-13 | — | — | US | claimed |
| US-20210139539-A1 | NEW ANTIBACTERIAL PRODUCTS | THE UNIVERSITY OF LIVERPOOL (GB) | 2021-05-13 | — | — | US | claimed |
| CN-110582506-A | Novel antimicrobial products | 林肯大学 | 2019-12-17 | — | — | CN | claimed |
| WO-2018162922-A1 | NEW ANTIBACTERIAL PRODUCTS | UNIVERSITY OF LINCOLN (GB) | 2018-09-13 | — | — | WO | claimed |
| CN-103379911-A | PGC-1 alpha modulating peptides | LIPOTEC SA | 2013-10-30 | — | — | CN | claimed |
| US-7052673-B2 | Pharmaceuticals for the imaging of angiogenic disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-05-30 | — | — | US | claimed |
| EP-1355638-B1 | ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES | MAGNESIUM DIAGNOSTICS INC (US) | 2006-05-03 | — | — | EP | claimed |
| US-20060003926-A1 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | LANTHEUS MEDICAL IMAGING, INC. | 2006-01-05 | — | — | US | claimed |
| US-20050118100-A9 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | LANTHEUS MEDICAL IMAGING, INC. | 2005-06-02 | — | — | US | claimed |
| EP-1068224-B1 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-05-11 | — | — | EP | claimed |
| US-20020106325-A1 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | CARPENTER ALAN P (US) | 2002-08-08 | — | — | US | claimed |
| WO-2002055111-A2 | SIMULTANEOUS IMAGING OF CARDIAC PERFUSION AND A VITRONECTIN RECEPTOR TARGETED IMAGING AGENT | BRISTOL MYERS SQUIBB MEDICAL I (US) | 2002-07-18 | — | — | WO | claimed |
| WO-2002011714-A2 | ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES | MAGNESIUM DIAGNOSTICS, INC. (US) | 2002-02-14 | — | — | WO | claimed |
| US-20020001566-A1 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-03 | — | — | US | claimed |
| WO-2001097860-A2 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS FOR USE IN COMBINATION THERAPY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | claimed |
| EP-1068224-A2 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | Du Pont Pharmaceuticals Company (US) | 2001-01-17 | — | — | EP | claimed |
| WO-1999058162-A2 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-11-18 | — | — | WO | claimed |
| CN-1234735-A | Method for treating skin pigmentation | JOHNSON & JOHNSON CONSUMER (US) | 1999-11-10 | — | — | CN | claimed |
| CN-1212262-A | Polyolefin synthetic resin composition containing clear nucleating agent | ATOCHEM ELF SA (FR) | 1999-03-31 | — | — | CN | claimed |
| CN-1192747-A | Peptidyl heterocyclic compounds for the treatment of thrombin-related diseases | ORTHO PHARMA CORP (US) | 1998-09-09 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139539-A1 | NEW ANTIBACTERIAL PRODUCTS | DBI, MRPL21, NRDC | LMNA 2247/4885PTGS1 908/4885ABCC4 167/4885 |
| US-20050118100-A9 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | TNNI3, ASGR1, TNNT2 | LMNA 285/4885PTGS1 3415/4885ABCC4 1858/4885 |
| US-20020106325-A1 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | TNNI3, ASGR1, TNNT2 | LMNA 285/4885PTGS1 3415/4885ABCC4 1858/4885 |
| US-11897970-B2 | Antibacterial products | DBI, PDIA5, ABCB11 | LMNA 1994/4885PTGS1 837/4885ABCC4 131/4885 |
| US-20020001566-A1 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | VEGFA, FLT4, FLT1 | LMNA 2389/4885PTGS1 502/4885ABCC4 933/4885 |
| US-20060003926-A1 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | FLT4, VEGFA, FLT1 | LMNA 1384/4885PTGS1 628/4885ABCC4 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.